Identifying individuals at high risk for diabetes - The Atherosclerosis Risk in Communities study

被引:376
作者
Schmidt, MI
Duncan, BB
Bang, H
Pankow, JS
Ballantyne, CM
Golden, SH
Folsom, AR
Chambless, LE
机构
[1] Univ Fed Rio Grande do Sul, Sch Med, Grad Studies Program Epidemiol, BR-90035003 Porto Alegre, RS, Brazil
[2] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Biostat, Sch Publ Hlth, Chapel Hill, NC USA
[4] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN USA
[5] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[6] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD USA
关键词
D O I
10.2337/diacare.28.8.2013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To develop and evaluate clinical rules to predict risk for diabetes in middle-aged adults. RESEARCH DESIGN AND METHODS - The Atherosclerosis Risk in Communities is a cohort study conducted from 1987-1989 to 1996-1998. We studied 7,915 participants 45-64 years of age, free of diabetes at baseline, and ascertained 1,292 incident cases of diabetes by clinical diagnosis or oral glucose tolerance testing. RESULTS - We derived risk functions to predict diabetes using logistic regression in a random half of the sample. Rules based on these risk functions were evaluated in the other half. A risk function based on waist, height, hypertension, blood pressure, family history of diabetes, ethnicity, and age was performed similarly to one based on fasting glucose (area under the receiver-operating characteristic curve [AUC] 0.71 and 0.74, respectively; P = 0.2). Risk functions composed of the clinical variables plus fasting glucose (AUC 0.78) and additionally including triglycerides and HDL cholesterol (AUC 0.80) performed better (P < 0.001). Evaluation of scores based on the metabolic syndrome as defined by the National Cholesterol Education Program or with slight variations showed AUCs of 0.75 and 0.78, respectively. Rules based on all these approaches, while identifying 20-56% of the sample as screen positive, achieved sensitivities of 40-87% and specificities of 50-86%. CONCLUSIONS - Rules derived from clinical information, alone or combined with simple laboratory measures, can characterize degrees of diabetes risk in middle-aged adults, permitting preventive actions of appropriate intensity. Rules based on the metabolic syndrome are reasonable alternatives to rules derived from risk functions.
引用
收藏
页码:2013 / 2018
页数:6
相关论文
共 22 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]   Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].
Buchanan, TA ;
Xiang, AH ;
Peters, RK ;
Kjos, SL ;
Marroquin, A ;
Goico, J ;
Ochoa, C ;
Tan, S ;
Berkowitz, K ;
Hodis, HN ;
Azen, SP .
DIABETES, 2002, 51 (09) :2796-2803
[4]   ADVANCES IN STATISTICAL METHODOLOGY FOR THE EVALUATION OF DIAGNOSTIC AND LABORATORY TESTS [J].
CAMPBELL, G .
STATISTICS IN MEDICINE, 1994, 13 (5-7) :499-508
[5]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]  
Efron B., 1994, INTRO BOOTSTRAP, DOI DOI 10.1201/9780429246593
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[10]  
Genuth S, 2003, DIABETES CARE, V26, P3160